NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has been included in the Mentor Capital Cancer Immunotherapy Index (the “Index”), an index of companies judged noteworthy by Mentor Capital that are predominantly involved in the cancer immunotherapy sector.
Mentor Capital states that the Index is calculated and presented based upon a theoretical $1,000 investment in each CI Index company starting at the time of Index formation on July 10, 2009 with mathematical adjustments for the addition of new companies.
On Advaxis’ inclusion into the Index, Mentor Capital Chairman/CEO and Founder Chester Billingsley said, “We have watched Advaxis Incorporated with positive anticipation over the last eighteen months as it increased its focus toward cancer therapy so that we could bring them into our Cancer Immunotherapy Index. As a scientist, I’m excited about including them as a strong new addition. Dr. Yvonne Paterson of the University of Pennsylvania has developed a promising immunotherapeutic platform and technology that lends itself to delivering immune triggers against a number of cancer antigens. As a natural result, Advaxis has, and we believe will continue to add, multiple drugs in clinic and collaborations with governments and leading institutions. The inherent ability to deliver against multiple cancer lines, the strong reported tumor defeating response, and the unique technology are similar to the advantages that delivered such a strong portfolio return for Mentor Capital from Dendreon (Nasdaq: DNDN) and Immuno Cellular Therapeutics (OTCBB: IMUC).”
The annualized Index return, since inception in 2009 has been 48%.
“This inclusion into the Mentor Capital Cancer Immunotherapy Index is a significant step forward for the Company,” said Chairman/CEO Thomas A. Moore. “We welcome the added visibility this will bring to our strong science and broad based clinical programs.”
About The Mentor Capital Immunotherapy Index
The Cancer Immunotherapy Index is an index of initially ten (10) companies known by Mentor Capital and judged to be substantially and predominantly involved in the cancer immunotherapy sector. A company that is not yet large enough or a company that is already larger but involved in mostly other things will not be included in the CI Index. Companies that grow, become more specialized in cancer immunotherapy or become better known to Mentor Capital may be added to the Index over time. For more information about the Index, please visit: http://www.mentorcapital.com/Cancer_Immunotherapy_Index.html.
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live but attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Our platform technology was developed by The University of Pennsylvania. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh, Cancer Research – UK, the University of British Columbia and the Department of Homeland Security. Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.